Skip to main content

Aimei Health Technology Co., Ltd.

For the period ended Mar 31, 2025. Filed May 14, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 14, 2025

AFJK$12.20-0.1%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits

Cover page

Show cover page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31,2025

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number:001-41880

(Exact name of registrant as specified in its charter)

Cayman IslandsN/A
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)

10 East 53rd Street, Suite 3001

New York, NY 10022

(Address of principal executive offices) (Zip Code)

86-13758131392

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each ClassTrading Symbol(s)Name of each exchange on which registered
Ordinary Shares, par value $0.0001 per shareAFJKThe Nasdaq Stock Market LLC
Rights, exchangeable into one-fifth of one Ordinary ShareAFJKRThe Nasdaq Stock Market LLC
Units, each consisting of one Ordinary Share and one RightAFJKUThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer☐Accelerated filer☐
Non-accelerated filer☒Smaller reporting company☒
Emerging growth company☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☒ No☐

As of May 14, 2025, there were 6,121,733 ordinary shares of the Company issued and outstanding.

Aimei Health Technology Co., Ltd

Form 10-Q

For the Quarterly Period Ended March 31, 2025

Contents

Part IFinancial Information1
Item 1Financial Statements1
Unaudited Balance Sheets as of March 31, 2025 and December 31, 20241
Unaudited Statements of Operations for the three months ended March 31, 2025 and 20242
Unaudited Statements of Changes in Shareholders’ Deficit for the three months ended March 31, 2025 and 20243
Unaudited Statements of Cash Flows for the three months ended March 31, 2025 and 20244
Notes to Unaudited Financial Statements5
Item 2Management’s Discussion and Analysis of Financial Condition and Results of Operations17
Item 3Quantitative and Qualitative Disclosures about Market Risk19
Item 4Controls and Procedures19
Part IIOther Information20
Item 1Legal Proceedings20
Item 1ARisk Factors20
Item 2Unregistered Sales of Equity Securities and Use of Proceeds20
Item 3Defaults Upon Senior Securities20
Item 4Mine Safety Disclosures21
Item 5Other Information21
Item 6Exhibits21
Signature22

i

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.